Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
10:40am, Friday, 01'st May 2026
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05am, Friday, 01'st May 2026
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
07:30am, Monday, 27'th Apr 2026
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced t
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
10:40am, Wednesday, 15'th Apr 2026
Here is how ADC Therapeutics SA (ADCT) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.
First Look: JPM risks, XWEL deal, UAL fares, SpaceX halo
07:37am, Monday, 06'th Apr 2026
Stock News JPMorgan flags key risks: JPMorgan Chase (JPM) CEO Jamie Dimon's annual letter warned on geopolitics, inflation, private markets and âpoor bank reg
ADC Therapeutics Announces New Employee Inducement Grant
04:05pm, Wednesday, 01'st Apr 2026
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
12:15pm, Friday, 27'th Mar 2026
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
10:40am, Friday, 13'th Mar 2026
Here is how ADC Therapeutics SA (ADCT) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
10:00am, Tuesday, 10'th Mar 2026
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
09:36am, Tuesday, 10'th Mar 2026
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.29 per share a year ago.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
07:30am, Tuesday, 10'th Mar 2026
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases s
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
07:15am, Tuesday, 03'rd Mar 2026
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Monday, 02'nd Mar 2026
LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
ADC Therapeutics to Participate in March Investor Conferences
07:15am, Tuesday, 24'th Feb 2026
LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced pa
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
07:15am, Monday, 23'rd Feb 2026
LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
